16/09/2026 Daiichi Sankyo Secures Japan Approvals for Enhertu and Datroway in First-Line Breast Cancer OncoC4 Receives US FDA Fast Track Designation for Cesalatamig in NSCLC Daiichi Sankyo Secures Japan Approvals for Enhertu and Datroway in First-Line Breast Cancer (Ref) Daiichi Sankyo announced the approval of two antibody-drug conjugates in Japan, expanding their use into the first-line metastatic breast cancer setting The approvals include Enhertu (trastuzumab deruxtecan)